History of the development of antiemetic guidelines at Mayo Clinic Rochester

Charles Lawrence Loprinzi, Steven Robert Alberts, Bradley J. Christensen, Lorelei J. Hanson, David R. Farley, Joan K. Broers, Donna L. Betcher, Robert E. Grady, Peter A. Southorn, Todd M. Johnson, Edith A. Perez

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5- hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy- induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.

Original languageEnglish (US)
Pages (from-to)303-309
Number of pages7
JournalMayo Clinic Proceedings
Volume75
Issue number3
StatePublished - 2000

Fingerprint

Antiemetics
Guidelines
Costs and Cost Analysis
Drug Therapy
Quality of Health Care
Nausea
Vomiting
Patient Care
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Loprinzi, C. L., Alberts, S. R., Christensen, B. J., Hanson, L. J., Farley, D. R., Broers, J. K., ... Perez, E. A. (2000). History of the development of antiemetic guidelines at Mayo Clinic Rochester. Mayo Clinic Proceedings, 75(3), 303-309.

History of the development of antiemetic guidelines at Mayo Clinic Rochester. / Loprinzi, Charles Lawrence; Alberts, Steven Robert; Christensen, Bradley J.; Hanson, Lorelei J.; Farley, David R.; Broers, Joan K.; Betcher, Donna L.; Grady, Robert E.; Southorn, Peter A.; Johnson, Todd M.; Perez, Edith A.

In: Mayo Clinic Proceedings, Vol. 75, No. 3, 2000, p. 303-309.

Research output: Contribution to journalArticle

Loprinzi, CL, Alberts, SR, Christensen, BJ, Hanson, LJ, Farley, DR, Broers, JK, Betcher, DL, Grady, RE, Southorn, PA, Johnson, TM & Perez, EA 2000, 'History of the development of antiemetic guidelines at Mayo Clinic Rochester', Mayo Clinic Proceedings, vol. 75, no. 3, pp. 303-309.
Loprinzi, Charles Lawrence ; Alberts, Steven Robert ; Christensen, Bradley J. ; Hanson, Lorelei J. ; Farley, David R. ; Broers, Joan K. ; Betcher, Donna L. ; Grady, Robert E. ; Southorn, Peter A. ; Johnson, Todd M. ; Perez, Edith A. / History of the development of antiemetic guidelines at Mayo Clinic Rochester. In: Mayo Clinic Proceedings. 2000 ; Vol. 75, No. 3. pp. 303-309.
@article{c7370d5a0b684bde82c6be916cbec82e,
title = "History of the development of antiemetic guidelines at Mayo Clinic Rochester",
abstract = "This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5- hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy- induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.",
author = "Loprinzi, {Charles Lawrence} and Alberts, {Steven Robert} and Christensen, {Bradley J.} and Hanson, {Lorelei J.} and Farley, {David R.} and Broers, {Joan K.} and Betcher, {Donna L.} and Grady, {Robert E.} and Southorn, {Peter A.} and Johnson, {Todd M.} and Perez, {Edith A.}",
year = "2000",
language = "English (US)",
volume = "75",
pages = "303--309",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - History of the development of antiemetic guidelines at Mayo Clinic Rochester

AU - Loprinzi, Charles Lawrence

AU - Alberts, Steven Robert

AU - Christensen, Bradley J.

AU - Hanson, Lorelei J.

AU - Farley, David R.

AU - Broers, Joan K.

AU - Betcher, Donna L.

AU - Grady, Robert E.

AU - Southorn, Peter A.

AU - Johnson, Todd M.

AU - Perez, Edith A.

PY - 2000

Y1 - 2000

N2 - This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5- hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy- induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.

AB - This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5- hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy- induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.

UR - http://www.scopus.com/inward/record.url?scp=0034090643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034090643&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 303

EP - 309

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -